Does vitamin E help with menopause hot flashes?

Not by an amount the best evidence can confirm. A 2022 meta-analysis of randomized trials in menopausal women found that vitamin E alone did not significantly reduce how often hot flashes came, with a standardized difference of -0.21 (95% CI -0.47 to 0.04), an interval that crosses zero. The largest single trial, in 120 breast cancer survivors taking 800 IU a day, found about one fewer hot flash a day than on placebo, and at the end the women did not prefer vitamin E over the dummy pill, 32 against 29 percent.

Unsettled. Several small Iranian trials did report fewer hot flashes on vitamin E, with 51, 84 and 93 women followed for 4 to 8 weeks. When trials like these are pooled the effect of vitamin E alone no longer reaches significance. The pooled analysis rests on small studies, mostly from Iran, and its authors call for larger trials, so the honest answer is a small effect at best, which nobody has confirmed in a large trial.

What the trials found

The pooled evidence

The 2022 meta-analysis searched English and Persian databases to March 2021 and pooled placebo controlled trials of oral vitamin E, omega-3 or both. For hot flash frequency on vitamin E alone the result was not significant. The one combination that worked was vitamin E taken together with omega-3, which lowered hot flash intensity, with a mean difference of -0.35 (95% CI -0.48 to -0.21) on the intensity scale, against placebo. That rests on 2 small studies, and we read only the abstract, which does not say how large that difference is in everyday terms.

A Cochrane review of 16 randomized trials of non-hormonal treatments in women with a history of breast cancer contained one vitamin E trial, and it showed no beneficial effect. In the same review, three groups of prescription drugs, SSRIs and SNRIs, clonidine and gabapentin, reduced the number and severity of hot flushes. A third review, from 2022, took in 16 studies of any design with doses from 10 mg to 400 IU. It pooled nothing and concluded only that vitamin E may influence hot flashes, that estrogen gave better results, and that good quality data are still needed.

The individual trials

The 800 IU trial in 120 breast cancer survivors is the largest. In the first period alone hot flashes fell 25 percent on vitamin E and 22 percent on placebo, a gap that was not significant (P = .90). Only the crossover analysis found the one fewer flash a day, and the authors judged that change minimal.

The smaller trials look better on paper. In 51 menopausal women, 400 IU a day for 4 weeks went with 3.19 hot flashes a day against 5.00 on placebo. Placebo always came first in that trial, and hot flashes often wane with time, so the order and the vitamin cannot be separated. In 93 postmenopausal women in Ahar, Iran, 200 IU of vitamin E for 8 weeks lowered the hot flash count against placebo, an adjusted difference of -8.7 (95% CI -0.6 to -15.0). At 4 weeks the difference had not reached significance (P = 0.052). In 84 postmenopausal women, 200 IU twice a day for 8 weeks reduced hot flashes by nearly one third of the starting count (P = 0.002). That card gives the share and no absolute numbers or interval, so we cannot tell you how many flashes a day one third was.

Who should be careful

The doses in these trials are not food amounts. The US National Institutes of Health Office of Dietary Supplements (NIH ODS) says large doses of vitamin E taken with warfarin or antiplatelet drugs can raise the risk of bleeding, and that the amount needed for that is unknown but probably above 400 IU a day. Several of the hot flash trials used 400 to 800 IU a day, at or above that line. NIH ODS also notes that two large long-term trials, in Finnish male smokers on 50 mg a day for about 6 years and in US male physicians on 400 IU every other day for 8 years, found more hemorrhagic strokes. Those were men, and no comparable trial exists in women taking vitamin E for hot flashes.

The upper limit depends on where you live. NIH ODS says up to 1,000 mg a day appears safe in adults, and adds that the data are limited and come from small groups followed for weeks or months. The European Food Safety Authority (EFSA) re-examined vitamin E in 2024 and kept its adult limit at 300 mg a day, set on bleeding risk. 800 IU of natural vitamin E is about 536 mg, above the European limit.

Short term, the trials saw little harm. In the 800 IU trial, 120 women checked for toxicity over 4 weeks showed none, and the 2022 meta-analysis reported no serious side effects. Both describe weeks, not years, and say nothing about long-term bleeding or stroke risk.

Not for everyone. If you take warfarin, another anticoagulant or an antiplatelet drug, vitamin E at the doses used for hot flashes is a question for your doctor before you start. If you have had breast cancer, the one vitamin E trial in that group found no benefit, while the Cochrane review found prescription options that did reduce hot flushes.

What expert bodies say

The North American Menopause Society, now The Menopause Society, said in 2004 that trial results were insufficient to support or refute vitamin E for hot flashes. Its 2023 position statement on non-hormone therapy lists supplements and herbal remedies as not recommended, and says hormone therapy remains the most effective treatment. The abstract we read groups vitamin E with supplements and does not name it, and we could not read the full text. French gynecology guidelines from 2021 (CNGOF and GEMVi) are more direct: they list vitamin E among approaches that appear ineffective for menopausal hot flushes, next to homeopathy, omega-3 and primrose oil.

Myth. Vitamin E is sometimes sold as a natural fix for hot flashes. The bodies that have looked at it do not recommend it, and the best pooled estimate for vitamin E alone does not reach significance.

How we searched

What would change this answer

• A large parallel-group randomized trial outside Iran, long enough to see past the natural easing of hot flashes over time. We found no such trial registered or under way.
• Crossover trials with a random order of treatments. In the 51 woman trial placebo always came first, which makes its drop hard to credit to vitamin E.
• A larger test of vitamin E together with omega-3, the one combination that lowered intensity in the pooled analysis, on the strength of 2 small studies.
• Safety data in women taking 400 to 800 IU for longer than a few weeks, since the bleeding and stroke signals come from years of use in men.

Sources

1. ev-veh-01 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials · n = —
   The mean frequency (MD: -0.50; 95% CI: -1.58 to 0.58) and intensity (SMD: -0.61; 95% CI: -1.50 to 0.29) of hot flushes in the omega-3 group and the frequency of hot flushes (SMD: -0.21; 95% CI: -0.47 to 0.04) in the vitamin E group showed no significant differences with the placebo.
   
   Who: menopausal women in randomized placebo-controlled trials of oral vitamin E, omega-3 or both
   Effect: hot flash frequency, vitamin E vs placebo: SMD -0.21 (95% CI -0.47 to 0.04), not significant; 10 studies in the review, 9 meta-analyzed
   Certainty: Best synthesis. Small trials, mostly from Iran; English and Persian databases searched to March 2021. Full text not in PMC, abstract numbers only.
   Post Reprod Health, 2022 · checked 2026-10-07 · we read the abstract
2. ev-veh-02 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials · n = 2 studies
   The results of the meta-analysis of two studies indicated that using vitamin E and omega-3 in combination significantly reduced the intensity of hot flushes compared to the placebo (mean difference (MD): -0.35; 95% CI: -0.48 to -0.21). ... No serious adverse effects were reported in the studies.
   
   Who: menopausal women in randomized placebo-controlled trials
   Effect: hot flash intensity, vitamin E plus omega-3 vs placebo: MD -0.35 (95% CI -0.48 to -0.21); 2 studies; no serious adverse effects reported
   Certainty: Combination signal rests on two small trials; authors call for larger RCTs. Absence of serious adverse effects reflects short trials, not long-term safety.
   Post Reprod Health, 2022 · checked 2026-10-07 · we read the abstract
3. ev-veh-03 · Meta-analysis or systematic review · Cochrane systematic review of randomized controlled trials · n = 16 RCTs
   Three pharmacological treatments (SSRIs and SNRIs, clonidine and gabapentin) reduced the number and severity of hot flushes. One study assessing vitamin E did not show any beneficial effect.
   
   Who: women with a history of breast cancer and hot flushes
   Effect: vitamin E: 1 RCT, no beneficial effect; clonidine, SSRIs/SNRIs and gabapentin reduced number and severity of hot flushes
   Certainty: Search to August 2008; results not pooled. The single vitamin E trial is Barton 1998 (ev-veh-05).
   Cochrane Database Syst Rev, 2010 · checked 2026-10-07 · we read the abstract
4. ev-veh-04 · Observational data · systematic review including all study designs, no meta-analysis · n = 16 studies
   Good quality data are needed to establish the benefits of vitamin E in the reduction of both the intensity and severity of hot flashes in menopausal woman, especially in the group of patients for whom the type of therapy should be selected very carefully in the context of their medical history.
   
   Who: postmenopausal women in studies of vitamin E supplementation
   Effect: qualitative synthesis, no pooled estimate; estrogen gave better clinical effects than vitamin E
   Certainty: Mixed designs (RCTs and non-randomized studies), doses 10 mg to 400 IU, heterogeneous controls; level C because the synthesis is not limited to RCTs.
   Nutrients, 2022 · checked 2026-10-07 · we read the fulltext
5. ev-veh-05 · Randomized controlled trial(s) · placebo-controlled randomized crossover trial, 4 weeks per arm · n = 120
   A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P < or = .05). At the study end, patients did not prefer vitamin E over the placebo (32% v 29%, respectively).
   
   Who: breast cancer survivors with hot flashes
   Effect: crossover analysis: about 1 fewer hot flash per day vs placebo (P <= .05); first period 25% vs 22% reduction (P = .90); preference 32% vs 29%
   Certainty: Largest single trial. Authors judge the clinical magnitude marginal.
   J Clin Oncol, 1998 · checked 2026-10-07 · we read the abstract
6. ev-veh-06 · Randomized controlled trial(s) · double-blind placebo-controlled crossover trial, placebo then vitamin E in fixed order, 4 weeks each · n = 51
   There were statistical significant differences in hot flashes severity score (2.37 +/- 0.74, 1.80 +/- 0.87) and their daily frequency (5.00 +/- 3.34, 3.19 +/- 2.74) after the treatments between the placebo and vitamin E therapies (p < 0.0001).
   
   Who: menopausal women with hot flashes
   Effect: daily frequency 5.00 +/- 3.34 (placebo) vs 3.19 +/- 2.74 (vitamin E); severity score 2.37 vs 1.80; p < 0.0001
   Certainty: Fixed sequence (placebo first) confounds with time; hot flashes often wane on their own. Small, single center.
   Gynecol Obstet Invest, 2007 · checked 2026-10-07 · we read the abstract
7. ev-veh-07 · Randomized controlled trial(s) · triple-blind randomized placebo-controlled trial, three arms, 8 weeks · n = 93
   Mean number of hot flashes in the curcumin group (adjusted mean difference = -10.7, 95%confidence interval = -3.6 to -17.9, P = 0.001) and in the vitamin E group (-8.7, -0.6 to -15.0, P = 0.029) was significantly lower than the placebo group after the intervention.
   
   Who: postmenopausal women, mean age 51.7 years, Ahar, Iran
   Effect: adjusted mean difference in hot flash number vs placebo -8.7 (95% CI -0.6 to -15.0), P = 0.029 at 8 weeks; at 4 weeks P = 0.052
   Certainty: Dose described both as 200 IU/day and twice daily in the abstract; small sample; no effect on anxiety or overall menopausal symptoms.
   Complement Ther Med, 2020 · checked 2026-10-07 · we read the abstract
8. ev-veh-08 · Randomized controlled trial(s) · triple-blind randomized placebo-controlled trial, three arms, 8 weeks · n = 84
   We conclude that vitamin E reduced the incidence of hot flashes by nearly one-third of the base amount.
   
   Who: postmenopausal women
   Effect: hot flash number reduced vs placebo (P = 0.002), about one third of baseline
   Certainty: No confidence interval in the abstract; small Iranian trial from the same research setting as ev-veh-07.
   Health Care Women Int, 2024 · checked 2026-10-07 · we read the abstract
9. ev-veh-09 · Position of an expert body · society position statement based on expert panel literature review · n = —
   Not recommended: Paced respiration (Level I); supplements/herbal remedies (Levels I-II); cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equol, cannabinoids, acupuncture, calibration of neural oscillations (Level II); chiropractic interventions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III).
   
   Who: menopausal women with vasomotor symptoms
   Effect: supplements/herbal remedies: not recommended (Levels I-II); hormone therapy remains most effective
   Certainty: Abstract groups vitamin E with supplements; the vitamin E-specific line in the paywalled full text was not read.
   Menopause, 2023 · checked 2026-10-07 · we read the abstract
10. ev-veh-10 · Position of an expert body · society position statement · n = —
    Among nonprescription remedies, clinical trial results are insufficient to either support or refute efficacy for soy foods and isoflavone supplements (from either soy or red clover), black cohosh, or vitamin E; however, no serious side effects have been associated with short-term use of these therapies.
    
    Who: menopausal women with vasomotor symptoms
    Effect: vitamin E: evidence insufficient either way; no serious side effects with short-term use
    Certainty: Superseded by the 2015 and 2023 statements; kept to show how the position moved.
    Menopause, 2004 · checked 2026-10-07 · we read the abstract
11. ev-veh-11 · Position of an expert body · clinical practice guideline (CNGOF and GEMVi) based on randomized trials and meta-analyses · n = —
    By contrast, other approaches, both pharmacological or non-pharmacological, appear to be ineffective in the management of HT. These include homeopathy, vitamin E, alanine, omega 3, numerous phytoestrogens (red clover, black cohosh…), primrose oil, physical activity.
    
    Who: menopausal women with hot flushes, including breast cancer survivors
    Effect: vitamin E grouped with homeopathy, omega 3 and primrose oil as appearing ineffective
    Certainty: Divergence: small trials report benefit, bodies do not recommend it.
    Gynecol Obstet Fertil Senol, 2021 · checked 2026-10-07 · we read the abstract
12. ev-veh-12 · Position of an expert body · government fact sheet · n = —
    As a result, taking large doses with anticoagulant or antiplatelet medications, such as warfarin (Coumadin), can increase the risk of bleeding, especially in conjunction with low vitamin K intake. The amounts of supplemental vitamin E needed to produce clinically significant effects are unknown but probably exceed 400 IU/day [61].
    
    Who: adults taking anticoagulant or antiplatelet medications
    Effect: bleeding risk with anticoagulants/antiplatelets; clinically significant amounts unknown, probably above 400 IU/day
    Certainty: The hot flash trials used 400-800 IU/day, at or above that threshold.
    NIH Office of Dietary Supplements, Vitamin E Fact Sheet for Health Professionals · checked 2026-10-07 · we read the section
13. ev-veh-13 · Position of an expert body · government fact sheet · n = —
    Two clinical trials have found an increased risk of hemorrhagic stroke in participants taking alpha-tocopherol; one trial included Finnish male smokers who consumed 50 mg/day for an average of 6 years [53] and the other trial involved a large group of male physicians in the United States who consumed 400 IU (180 mg) of synthetic vitamin E every other day for 8 years [26].
    
    Who: Finnish male smokers; US male physicians
    Effect: increased hemorrhagic stroke risk at 50 mg/day for about 6 years and 400 IU every other day for 8 years
    Certainty: Long-term data in men; no equivalent trial in menopausal women taking vitamin E for hot flashes.
    NIH Office of Dietary Supplements, Vitamin E Fact Sheet for Health Professionals · checked 2026-10-07 · we read the section
14. ev-veh-14 · Position of an expert body · government fact sheet · n = —
    Doses of up to 1,000 mg/day (1,500 IU/day of the natural form or 1,100 IU/day of the synthetic form) in adults appear to be safe, although the data are limited and based on small groups of people taking up to 3,200 mg/day of alpha-tocopherol for only a few weeks or months.
    
    Who: adults
    Effect: up to 1,000 mg/day (1,500 IU natural, 1,100 IU synthetic) appears safe; data limited
    Certainty: US ceiling; EFSA sets 300 mg/day (ev-veh-15). 800 IU natural vitamin E is about 536 mg, above the EFSA limit.
    NIH Office of Dietary Supplements, Vitamin E Fact Sheet for Health Professionals · checked 2026-10-07 · we read the section
15. ev-veh-15 · Position of an expert body · EFSA scientific opinion on the tolerable upper intake level · n = —
    Considering the totality of the available evidence and related uncertainties (Section 3.4 ), the Panel thus retains the UL previously established by the SCF of 300 mg α‐tocopherol/day for adults.
    
    Who: adults in the European Union, including pregnancy and lactation
    Effect: UL 300 mg alpha-tocopherol/day retained; based on bleeding-time studies
    Certainty: Bodies disagree on the ceiling by a factor of more than three. The 400 IU doses in hot flash trials sit near the EFSA limit; 800 IU exceeds it.
    EFSA NDA Panel, Scientific opinion on the tolerable upper intake level for vitamin E, EFSA Journal 2024 (CC BY-ND 4.0) · checked 2026-10-07 · we read the fulltext
16. ev-veh-16 · Randomized controlled trial(s) · placebo-controlled randomized crossover trial · n = 120
    The 120 patients evaluated for toxicity failed to show any.
    
    Who: breast cancer survivors with hot flashes
    Effect: no toxicity detected over 4 weeks at 800 IU/day
    Certainty: Short exposure only; does not address long-term bleeding or stroke risk.
    J Clin Oncol, 1998 · checked 2026-10-07 · we read the abstract